Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press10210.17650/1994-4098-2012-0-2-65-69GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕTreatment results and prognostic factors of clear cell ovarian carcinomas and ovarian carcinomas with clear cell componentСветлоклеточный рак яичников и смешанные опухоли яичников со светлоклеточным компонентом: результаты лечения, факторы прогнозаAhmedovaM. D.АхмедоваМ. Д.
Russian Federation
ShabanovM. A.ШабановМ. А.
Russian Federation
BarinovV. V.БариновВ. В.
Russian Federation
ZhordaniaK. I.ЖорданиаК. И.
Russian Federation
BokinaL. I.БокинаЛ. И.
Russian Federation
MustafinaE. A.МустафинаЕ. А.
Russian Federation
afl_nlo154@mail.ruBokinI. I.БокинИ. И.
Russian Federation
OlkinD. B.ОлькинД. Б.
Russian Federation
Federal State Budgetary Institution N.N. Blokhin Russian Cancer Research Center under Russian Academy of Medical Sciences, MoscowФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва230520122656923072014230720142012https://ojrs.abvpress.ru/ojrs/article/view/102

The most important prognostic factors for clear cell carcinoma (CCC) are clinical and morphological signs and clinical stage of the disease. Analyses of 5-year survival in patients with I stage of CCC is 69 %, in II stage – 55 %, in III stage – 14 % and in IV stage – 4 % patients. We analyzed distant results of treatment of 71 patients with CCC and of 25 patients with mixed malignant ovaries neoplasm with obligatory clear cell component taking into consideration main clinical and morphological sings of disease. On the base of performed reseal we revealed that morphological structure of the tumors and stage of the disease exerted heist influence on the exponent of survival of the patients with clear CCC ovaries neoplasm. Besides, there is a correlation between exponent of patients’ survival and radicalized of surgery, character of tumor growth, differentiation degree, cell anaplasia and mitotic activity of tumor cells.

Наиболее важными прогностическими факторами для светлоклеточных аденокарцином яичников (САЯ) являются клинико-морфологические признаки и клиническая стадия заболевания. Показатель 5-летней выживаемости у пациенток с I стадией САЯ составляет 69 %, при II стадии – 55 %, при III – 14 % и при IV – 4 %. Нами проанализированы отдаленные результаты лечения 71 больной с САЯ и 25 пациенток со смешанными злокачественными эпителиальными опухолями яичников с обязательным светлоклеточным компонентом. На основании проведенного исследования установлено, что на показатель выживаемости больных со светлоклеточными новообразованиями яичников наибольшее влияние оказывают морфологическое строение опухоли и стадия заболевания. Кроме того, отмечена корреляция между показателем выживаемости пациенток со светлоклеточными новообразованиями яичников и радикальностью оперативного вмешательства, характером роста опухоли, степенью дифференцировки опухоли, клеточной анаплазии и митотической активностью опухолевых клеток.

clear cell carcinoma ovariansurvivalprognostic factorsсветлоклеточная аденокарцинома яичниковвыживаемостьфакторы прогноза1. Matsuura Y., Robertson G., Marsden D.E. et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2006;103(2):740–4.Matsuura Y., Robertson G., Marsden D.E. et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2006;103(2):740–4.2. Komiyama S.-I., Aoki D., Tominaga E. et al. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: Clinicopathologic evaluation. Gynecol Oncol 1999;72:342–6.Komiyama S.-I., Aoki D., Tominaga E. et al. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: Clinicopathologic evaluation. Gynecol Oncol 1999;72:342–6.3. Kennedy A.W., Biscotti C.V., Hart W.R., Tuason L.J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993;50(3):334–8.Kennedy A.W., Biscotti C.V., Hart W.R., Tuason L.J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993;50(3):334–8.4. Kennedy A.W., Biscotti C.V., Hart W.R. et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342–9.Kennedy A.W., Biscotti C.V., Hart W.R. et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342–9.5. Nolan L.P., Heatley M.K. The value of immunocytochemistry in olistinguishing between clear cell carcinoma of the ovary and kidney. Int J Gynecol Pathol 2001;20(2):155–9.Nolan L.P., Heatley M.K. The value of immunocytochemistry in olistinguishing between clear cell carcinoma of the ovary and kidney. Int J Gynecol Pathol 2001;20(2):155–9.6. Norris H.J., Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1972;28:1074–81.Norris H.J., Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1972;28:1074–81.7. Parker T.M., Dockerty M.B., Randall L.M. Mesonephric clear cell carcinoma of the ovary. Am J Obstet Gynecol 1960;80:417–25.Parker T.M., Dockerty M.B., Randall L.M. Mesonephric clear cell carcinoma of the ovary. Am J Obstet Gynecol 1960;80:417–25.8. Goff B.A., Sainz de la Cuesta R., Muntz H.G. et al. Clear cell carcinoma of the ovary: a distinct histilogic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60(3):412–7.Goff B.A., Sainz de la Cuesta R., Muntz H.G. et al. Clear cell carcinoma of the ovary: a distinct histilogic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60(3):412–7.9. Novak E.R., Woodruff J.D. Mesonephroma of the ovary. Am J Obstet Gynecol 1959;77:632–44.Novak E.R., Woodruff J.D. Mesonephroma of the ovary. Am J Obstet Gynecol 1959;77:632–44.10. Aure J.C., Hoeg K., Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Cynecol 1971;37:860–7.Aure J.C., Hoeg K., Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Cynecol 1971;37:860–7.11. Kaku S., Hirai Y., Fujimoto Z. et al. Clinicopathological study on clear cell cfrcinoma of the ovary. Nippon Sanka Fujinka Gakkai Zasshi 1989;41(7):875–80.Kaku S., Hirai Y., Fujimoto Z. et al. Clinicopathological study on clear cell cfrcinoma of the ovary. Nippon Sanka Fujinka Gakkai Zasshi 1989;41(7):875–80.12. Короленкова Л.И. Светлоклеточные (мезонефроидные) опухоли женских половых органов. Автореф. дис. ... канд. мед. наук. М., 1983.Короленкова Л.И. Светлоклеточные (мезонефроидные) опухоли женских половых органов. Автореф. дис. ... канд. мед. наук. М., 1983.13. Rogers L.W., Julian C.G., Woodruff J.D. Mesonephroid carcinoma of the ovary. A study of 95 cases from the Emil Novak ovarian tumour registry. Gynecol Oncol 1972;1:76–89.Rogers L.W., Julian C.G., Woodruff J.D. Mesonephroid carcinoma of the ovary. A study of 95 cases from the Emil Novak ovarian tumour registry. Gynecol Oncol 1972;1:76–89.14. Eastwood G. Mesonephroid (clear cell) carcinoma of the ovary and endometrium. Cancer 1978;41:1911–28.Eastwood G. Mesonephroid (clear cell) carcinoma of the ovary and endometrium. Cancer 1978;41:1911–28.15. Lee R.A., Dockerty M.D., Wilson R.B., Symmonds R.E. Mesonephroma of the ovary. Am J Obstet Gynecol 1962;82:677–81.Lee R.A., Dockerty M.D., Wilson R.B., Symmonds R.E. Mesonephroma of the ovary. Am J Obstet Gynecol 1962;82:677–81.16. Huang Y.J., Ho C.M., Chen T.C. et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel- platinum-based. Gan To Kadaku Ruoho 1997;24(Suppl 1):70–3.Huang Y.J., Ho C.M., Chen T.C. et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel- platinum-based. Gan To Kadaku Ruoho 1997;24(Suppl 1):70–3.17. Okuda T., Saito H., Sekizawa A. et al. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: Immunohistochemical Study. Gynecol Oncol 2001;82:427–34.Okuda T., Saito H., Sekizawa A. et al. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: Immunohistochemical Study. Gynecol Oncol 2001;82:427–34.18. Deguchi M., Matsumoto Y., Ishiko O., Ogita S. Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis. Oncol Rep 2000;7(3):651–4.Deguchi M., Matsumoto Y., Ishiko O., Ogita S. Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis. Oncol Rep 2000;7(3):651–4.19. Fine G., Clarke H., Horn R. Mesonephroma of the ovary. Cancer 1973;31:398–410.Fine G., Clarke H., Horn R. Mesonephroma of the ovary. Cancer 1973;31:398–410.20. Doshi N., Tobon H. Primary clear cell carcinoma of the ovary. Cancer 1977; 39:2658–66.Doshi N., Tobon H. Primary clear cell carcinoma of the ovary. Cancer 1977; 39:2658–66.21. Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175–8.Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175–8.22. Pettersson F. Annual report of the results of treatment in gynecological cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1991.Pettersson F. Annual report of the results of treatment in gynecological cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1991.23. Shumizu Y., Umezawa S., Utsugi K. et al. Combination of CPT-11 with mitomycin-c (MMC) for platinum-refractory clear cell and mucinous adenocarcinoma of the ovary. Proc Am Soc Clin Oncol 1999;18:361;Shumizu Y., Umezawa S., Utsugi K. et al. Combination of CPT-11 with mitomycin-c (MMC) for platinum-refractory clear cell and mucinous adenocarcinoma of the ovary. Proc Am Soc Clin Oncol 1999;18:361;abstr 1393.24. Imachi M., Tsukamoto N., Shimamoto T. et al. Clear cell carcinoma of the ovary: a clinicopathologic analysis of 34 cases. Int J Gynecol Oncol 1991;1:113–9.Imachi M., Tsukamoto N., Shimamoto T. et al. Clear cell carcinoma of the ovary: a clinicopathologic analysis of 34 cases. Int J Gynecol Oncol 1991;1:113–9.25. Klemi P.J., Gronroos M. Mesonephroid carcinoma of the ovary. A clinicopathologic, histochemical and electron microscopic study. Obstet Gynecol 1979;53(4):472–9.Klemi P.J., Gronroos M. Mesonephroid carcinoma of the ovary. A clinicopathologic, histochemical and electron microscopic study. Obstet Gynecol 1979;53(4):472–9.26. Montag A.G., Jenison E.L., Griffiths C.T. et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol 1989;8(2):85–96.Montag A.G., Jenison E.L., Griffiths C.T. et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol 1989;8(2):85–96.27. Obrien M.E., Schofield J.B., Tan S. et al. Clear cell epithelial ovarian carcinoma (mesonephroid) bad prognosis only in early stages. Gynecol Oncol 1993;49:250–4.Obrien M.E., Schofield J.B., Tan S. et al. Clear cell epithelial ovarian carcinoma (mesonephroid) bad prognosis only in early stages. Gynecol Oncol 1993;49:250–4.28. Shiromizu K., Sugase M., Kawana T. et al. Clinicopathologic study of meso- nephric adenocarcinoma. J Jap Soc Cancer Ther 1977;9:271.Shiromizu K., Sugase M., Kawana T. et al. Clinicopathologic study of meso- nephric adenocarcinoma. J Jap Soc Cancer Ther 1977;9:271.